BMS’ deucravacitinib psoriasis pill could launch next year after outperforming Amgen’s rivalBristol-Myers Squibb has phase 3 data from its deucravacitinib psoriasis pill, showing it outperformed Amgen’s rival Otezla in Share XBMS’ deucravacitinib psoriasis pill could launch next year after outperforming Amgen’s rivalhttps://pharmaphorum.com/news/bms-deucravacitinib-psoriasis-pill-could-launch-next-year-after-outperforming-amgens-rival/
